Clinical trial
An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis
NCT05421858 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis
- Lead sponsor
- Basilea Pharmaceutica
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 11, 2024
- Completion date
- January 30, 2028
- Enrollment
- 450 (estimated)
- Sites
- 146
Conditions
As the registry lists them; a condition with its own page is linked.